Figure 1.

CVB1-6 seropositivity in CF and healthy control cohorts

Serum was extracted from blood-samples collected at yearly check-up appointments in the CF cohort (n = 65) or from samples taken from healthy individuals (n = 33) included in other studies at the Karolinska Institute. CVB1-6 seropositivity was examined by measuring the presence of neutralizing antibodies against the CVB1-6 viruses, using a standard plaque reduction assay. The cut-off titer for seropositivity was set to ≥1:16 for all six serotypes. The pie charts show the fraction of individuals that were positive for each CVB serotype in the two groups (blue color) and the white numbers show the exact percentage of positive cases in each group. See also Figure S1.